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Targeting gene transcription: a new strategy to down-regulate c-erbB-2
expression in mammary carcinoma
DP Hollywood* and HC Hurst
Gene Transcription Laboratory, ICRF Oncology Unit, Hammersmith Hospital, London W12 ONN, UK.
Summary Overexpression of the c-erbB-2 proto-oncogene in mammary carcinoma is frequently associated
with amplification of the c-erbB-2 gene, but it also occurs from a single-copy gene. Studies in mammary-
derived cell lines have shown that, whether or not the gene is amplified, there is a 6- to 8-fold increase in the
accumulation of c-erbB-2 mRNA per gene copy in overexpressing cells. We have recently shown that this
phenomenon is due to increased activity of the c-erbB-2 promoter mediated by the binding of a novel
transcription factor, OB2-1, which is present at higher levels in overexpressing cells than in low expressors.
OB2-1 activity therefore represents a novel therapeutic target for the down-regulation of c-erbB-2 levels in
human cells. As a prototype for this strategy, we show here that the drug sodium aurothiomalate is able to
inhibit the DNA-binding activity of OB2-1 in vitro and also to interfere with c-erbB-2 promoter activity in
cell-based transfection assays. In addition, endogenous c-erbB-2 immunoreactivity was reduced in cells treated
with aurothiomalate as compared with the levels observed in control cells.
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The c-erbB-2/HER-2 proto-oncogene encodes a 185 kDa
transmembrane tyrosine kinase growth factor receptor (pl85C-
erbB-2) and is the human counterpart of rodent c-neu. Abnor-
malities of pl85-erbB-2 expression primarily result from tran-
scriptional deregulation and/or gene amplification (Kraus et
al., 1987; Tal et al., 1987; Parkes et al., 1990; Pasleau et al.,
1993), and this has been implicated in the pathogenesis of a
number ofadult human tumours, including breast (Slamon et
al., 1987), stomach (Yonemura et al., 1991), ovary (Slamon
et al., 1989), bladder (Wright et al., 1991) and salivary gland
carcinoma (Sugano et al., 1992). In most tumour types,
p185cerbB-2 immunoreactivity has been associated with a
higher grade of histological appearance. Moreover, several
retrospective clinical studies of breast adenocarcinoma
patients have indicated that p185c,rbB-2 overexpression cor-
relates with a reduced overall and reduced disease-free sur-
vival (Perren, 1991; Press et al., 1993) and a more limited
response to adjuvant cytotoxic and hormonal therapies
(Wright et al., 1989, 1992; Gusterson et al., 1993).
The importance of the role played by p185crbB-2 in cellular
transformation is supported by several experimental observa-
tions. Firstly, c-erbB-2 overexpression leads to the transfor-
mation of NIH3T3 cells (Di Fiore et al., 1987; Di Marco et
al., 1990) and to the formation of a novel tumorigenic
phenotype in the immortalised MTSV1.7 human mammary
epithelial cell line (D'Sousa et al., 1993; D'Sousa and Taylor-
Papadimitriou, 1994). Secondly, c-neu/c-erbB-2 transgenic
mice develop a spectrum of tumours including early and
bilateral mammary gland tumours (Bouchard et al., 1989;
Tsuda et al., 1990). These results support the hypothesis that
c-erbB-2 overexpression plays an important role in the
pathogenesis of specific human tumours. This has provided
the rationale for the development of novel therapeutic
approaches which may inhibit either c-erbB-2 function, for
example monoclonal antibodies, dimerisation inhibitors,
tyrosine kinase inhibitors (Drebin et al., 1988; Hancock et
al., 1991; Wels et al., 1992), or c-erbB-2 mRNA expression,
for example antisense and antigene oligonucleotides (Bertram
et al., 1994).
Recently we have identified a positively acting transcrip-
tion factor, OB2-1, that binds to the c-erbB-2 promoter and
is responsible for the increase in c-erbB-2 transcription
observed in c-erbB-2-overexpressing human breast carcinoma
cell lines (Hollywood and Hurst, 1993). An alternative way
of down-regulating c-erbB-2 gene expression therefore may
be to reduce its transcription using drugs that alter the
function of the OB2-1 transcription factor. In this paper we
describe our initial studies examining this approach and show
that sodium aurothiomalate diminishes OB2-1-dependent c-
erbB-2 transcription by interfering with the DNA-binding
activity of OB2-1. Moreover, addition of aurothiomalate to a
mammary tumour-derived cell line resulted in a significant
reduction in c-erbB-2 immunoreactivity within the treated
cells. This is the first practical demonstration that targeting
c-erbB-2 expression at the level of transcription may be a
useful strategy in designing specific therapies against c-erbB-
2-positive human tumours.
Materials and methods
Cell culture
ZR75-1 cells were obtained from Dr Malcolm Parker (ICRF,
London, UK) and grown in 2% RPMI supplemented with
10% fetal calf serum (FCS). MDA MB 453 cells were
obtained from the ATCC and maintained in Dulbecco'sX
modified Eagle medium (DMEM) plus 10% FCS.
Sodium aurothiomalate/thiomalic acid
Sodium aurothiomalate (Sigma) and its parent compound,
thiomalic acid (Sigma), were resuspended in sterile deionised
water to create 0.5 M stock solutions and stored at 4°C.
Aliquots were freshly diluted in gel retention buffer (GRB;
25 mM Hepes pH 7.9, 1 mM EDTA, 5 mM dithiothreitol,
150 mM potassium chloride, 10% glycerol) to the desired
concentration immediately before their use in electromobility
shift assays (EMSAs).
Electromobility shift assays (EMSAs)
OB2-1 (Hollywood and Hurst, 1993) and ATF-I (Hurst et
al., 1991) binding assays were carried out as described
previously using 32P-labelled double-stranded oligonucleotide
probes to each binding site. OB2-1 was affinity purified from
ZR75-1 as described elsewhere (Bosher et al., 1995). ATF-1
was made in rabbit reticulocyte lysates (Hurst et al., 1991).
Proteins were incubated in GRB with aurothiomalate or
Correspondence: HC Hurst
*Present address: St Luke's Hospital, Highfield Road, Rathgar,
Dublin 6, Eire
Received 19 September 1994; revised 22 November 1994; accepted 23
November 1994Transcrptional down-regulation of the c-erbB-2 gene
DP Hollywood and HC Hurst
thiomalic acid for 1 h on ice before addition of probe.
Incubations were continued for a further 20 min followed by
electrophoresis on 8% (44:0.8) polyacrylamide gels in
0.5 x TBE. Gels were fixed and dried for autoradio-
graphy.
Short-term transfection assays
MDA MB 453 cells were subcultured on day 1 and standard
calcium phosphate precipitation protocols (Ausubel et al.,
1987) were used for transfection 24 h later on day 2. The
effect of aurothiomalate/thiomalic acid on c-erbB-2 promoter
function was examined using p300CAT (15pg), a 300 bp
c-erbB-2 promoter-chloramphenicol acetyltransferase (CAT)
construct (Hollywood and Hurst, 1993). In a separate series
of experiments, pE4CAT (15fig), a control reporter con-
struct, was used to monitor non-specific down-regulation of
transcription (Lee et al., 1989). All experiments included the
co-transfection of 3fig ofJATLacZ, a ,B-galactosidase expres-
sion plasmid, to control for variations in transfection effic-
iency. Corrected CAT activity was calculated using the galac-
tosidase (Gal) activity of each transfection (Hollywood and
Hurst, 1993).
On day 3, 24h after transfection, the cells were washed
with serum-free medium and switched to fresh DMEM plus
1% FCS, with either no added drug, 200 JIM aurothiomalate
or 200 JIM thiomalic acid. Reduced FCS was used to limit the
sequestration of aurothiomalate by albumin (Sadler, 1982;
Crooke, 1986), previous experiments having shown that
MDA MB 453 cells grow normally in medium supplemented
with 1% FCS (data not shown). Cells were cultured for a
further 48 h before harvesting on day 5. CAT and Gal assays
were performed as previously described (Hollywood and
Hurst, 1993). Each transfection was performed in duplicate
and all transfections were repeated at least three times with
different preparations ofplasmid DNA. The mean and standard
error of the mean (s.e.m.) of the corrected results are present-
ed. The transfection protocol is summarised in Figure 1.
Immunohistochemistry studies
MDA MB 453 cells were grown in standard culture condi-
tions (DMEM + 10% FCS) until 50-70% confluent and
then in DMEM + 1% FCS with either no supplement,
200,UM aurothiomalate or 200JIM thiomalic acid for a fur-
ther 72 h. Cells were sequentially washed with fresh DMEM
and PBS. Cell pellets in agarose plugs were fixed in formalin
and embedded in paraffin blocks. Sections were first incu-
bated with affinity-purified rabbit polyclonal antibody to the
c-erbB-2 21N peptide (Gullick et al., 1987), at 5-10JIgml-'
in phosphate-buffered saline with 0.5% bovine serum albu-
min (BSA) for 1 h at room temperature. The second incuba-
tion used biotinylated anti-rabbit antibody (Dako) and the
third a horseradish peroxidase-conjugated ABC kit (Dako).
The complex was visualised with diaminobenzidine tetra-
chloride solution and sections were counterstained with
Mayer's haematoxylin. Negative controls (not shown) com-
prised serial sections incubated with buffer alone instead of
the primary antibody and with the primary antibody blocked
by binding in the presence of an excess of the 21N pep-
tide.
Results
Aurothiomalate can reduce OB2-1 DNA-binding activity
In this study we sought to interrupt the activity of the
c-erbB-2 promoter in overexpressing cells by targeting the
activity of the OB2-4 transcription factor. Many transcrip-
tion factors require metal coordination for their structural
integrity (Harrison, 1991) or as co-factors for optimal DNA-
binding activity (Berg, 1986). In initial experiments we there-
fore examined metal chelators and drugs with metal ion
interactions to determine whether they could interrupt OB2-1
DNA binding activity and thereby provide a novel approach
to interfering with c-erbB-2 transcription.
A number ofcompounds were tested, including EDTA and
cis-platinum, and were found to have no affect on OB2-1
activity. In contrast, the colloidal gold drug, sodium
aurothiomalate, was shown to be particularly effective at
abolishing the DNA binding activity of OB2-1 (Figure 2).
Affinity-purified OB2-1 was incubated with a range of con-
centrations of either aurothiomalate (lanes 1-7) or the
parent compound thiomalic acid (lane 8). Labelled OB2-1
double-stranded oligonucleotide binding site probe was then
added to the incubations and the complexes separated on a
non-denaturing gel (EMSA assay; see Materials and
methods). Total inhibition of OB2-1-DNA complex forma-
tion was observed with 50 JIM aurothiomalate (lane 5),
whereas 100AM thiomalic acid (lane 8) had no effect on
OB2-1-binding activity. In order to assess whether the reduc-
tion in OB2-1-DNA binding was protein specific, we also
examined the effect of aurothiomalate and thiomalic acid on
the DNA-binding activity of in vitro synthesised ATF-1
(Figure 2, lanes 9-16). ATF-1 is a bZIP (leucine zipper
containing) transcription factor and its DNA binding is not
thought to be metal dependent (Hurst et al., 1991). In con-
trast to OB2-1, neither aurothiomalate (lanes 9-15) nor
thiomalic acid (lane 16) reduced ATF-1 binding. Another
bZIP factor, CREB, behaved similarly in this assay (data not
shown). These results clearly indicate that aurothiomalate is
capable ofaltering OB2-1-DNA binding activity and suggest
that it has a degree of specificity for OB2-1. In addition, the
AuTM TMA AuTM TMA
Split Transfect
cells cells
Day 1 Day 2
Harvest
cells
ID ;
Day 3 Day 4 Day 5
-l OB2-1 ATF-1
Wash cells and transfer to
DMEM+1% FCS
Add 200 gM sodium
aurothiomalate or 200 gM
thiomalic acid
10% FCS 1.0% FCS
Figure 1 Summary of MDA MB453 transfection protocol.
Figure 2 The effect of aurothiomalate on the DNA-binding
activity of OB2-1 and ATF-1. Lanes 1 -8 contained equal
amounts of affinity-purified OB2-1 protein and lanes 9-16 con-
tained equal amounts of in vitro-translated ATF-1. Proteins were
incubated on ice for I h in GRB with increasing amounts of
aurothiomalate as follows: lanes I and 9, no addition; lanes 2 and
10, 5 IM; lanes 3 and 11; 1O IM; lanes 4 and 12, 25 JM; lanes 5
and 13, 50jM; lanes 6 and 14, 75 #M; lanes 7 and 15, 1OOJIM;
lanes 8 and 16, 100 JIM thiomalic acid. Specific binding site
probes were then added followed by electrophoresis to separate
protein-DNA complexes from free probe which runs at the dye
front.
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754inability of thiomalic acid to disrupt OB2-1 binding suggests
that this action depends upon the presence of the specific
gold moiety, Au(I), in aurothiomalate.
Effect ofaurothiomalate on c-erbB-2 promoter activity
In view of the reduction of OB2-1 -DNA binding activity, we
next examined whether aurothiomalate was capable of down-
regulating c-erbB-2 promoter activity using a CAT reporter
transfection assay (Hollywood and Hurst, 1993). As auro-
thiomalate can interfere with steroid-dependent gene expres-
sion (Handel et al., 1991) the use of breast cell lines
dependent on oestrogen for growth would prejudice our
experiments. Consequently, the oestrogen receptor-negative,
c-erbB-2-overexpressing cell line MDA MB 453 was chosen
for the transient transfection assays. Previous studies have
shown that these cells have high levels of OB2-1-DNA
binding activity (Hollywood and Hurst, 1993). A c-erbB-2
promoter construct (p300CAT) that contains sequences
between - 300 and +40 (with the OB2-1-DNA binding site
at position -213) was selected for study as this minimal
promoter length retains full c-erbB-2 promoter activity
(Hollywood and Hurst, 1993). To control for non-specific
down-regulation of gene transcription, we also used a control
reporter plasmid, pE4CAT (Lee et al., 1989). This contains
the adenovirus early gene E4 promoter, whose activity is
largely based on the binding of the ATF/CREB family of
transcription factors (Lee et al., 1989). It should therefore be
unaffected by aurothiomalate as the binding activity of these
factors was not sensitive to the drug (Figure 2).
Following transient transfection of p300CAT and
pE4CAT, CAT accumulation was examined under three
different conditions: (a) no added thiolate compound; (b)
200gM aurothiomalate; and (c) 200liM thiomalic acid. The
results are summarised in Figure 3. Firstly, in the presence of
200tLM aurothiomalate, p300CAT activity was reduced to
25-30% of that observed with no added drug, whereas
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200!LM thiomalic acid had no significant effect. In addition,
neither aurothiomalate nor thiomalic acid significantly
altered pE4CAT activity, showing that the results with
p300CAT are specific and not due to an effect of the drug on
the viability of the MDA MB 453 cells or general, non-
specific interference with cellular transcription. We conclude
therefore that the activity of the c-erbB-2 promoter is
significantly reduced in the presence of aurothiomalate.
Effect ofaurothiomalate and thiomalic acid onpJ85cerbB-2
immunoreactivity
Given that aurothiomalate diminished the activity of a trans-
fected c-erbB-2 CAT reporter system, we next examined
whether the drug could affect endogenous c-erbB-2 expres-
sion. The expression of the c-erbB-2 gene following drug
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Figure 3 The effect of aurothiomalate on c-erbB-2 promoter
activity. MDA MB 453 cells were transiently transfected with
15fig of the reporter plasmids p300CAT or pE4CAT (see
Materials and methods). After transfection the cells were switch-
ed to low-serum medium and grown either with no further
supplement or the addition of either 2001LM aurothiomalate or
200 tLM thiomalic acid before harvesting. Cell lysates were assayed
for CAT activity. The results from the transfections in supple-
mented media are shown relative to the CAT activity of transfec-
tions of each reporter in non-supplemented medium which were
set at 100% in each case.
Figure 4 The effect of aurothiomalate on endogenous c-erbB-2
expression. MDA MB 453 cells were grown in low serum medium
with either no supplement (a) or with the addition of either
200 LM thiomalic acid (b) or 200 yM aurothiomalate (c). The
panels show cells immunostained for c-erbB-2 protein.
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exposure was determined at the protein level by immuno-
histochemical staining using the rabbit polyclonal 21N
antibody (Gullick et al., 1987). The MDA MB 453 cell line
was incubated with either no added drug, 200 LM aurothio-
malate or 200 JM thiomalic acid for 3 days before cell
harvesting. Cellular viability over the drug time course was
confirmed by direct light microscopy and haematoxylin stain-
ing (data not shown). Staining with the 21N antibody reveal-
ed the typical pl85c-erbB-2 membrane staining pattern in those
cells incubated with either no added drug or with 2001AM
thiomalic acid (Figure 4a and b). In contrast, the cells treated
with 200JAM aurothiomalate showed a markedly different
p185-erbB-2 distribution (Figure 4c) with reduced overall stain-
ing and a particularly marked reduction in membrane stain-
ing.
Discussion
In this paper we report that a gold-containing drug (sodium
aurothiomalate) diminishes the DNA-binding activity of
OB2-1, a positively acting transcription factor that is selec-
tively up-regulated in c-erbB-2-overexpressing breast carcin-
oma cell lines. Sodium aurothiomalate also reduces c-erbB-2
promoter activity in the MDA MB 453 mammary tumour
line, which has elevated OB2-1-DNA binding activity
(Hollywood and Hurst, 1993). In addition, short-term auro-
thiomalate exposure results in a pronounced change in
p185c-erbB-2 immunoreactivity at the cell membrane of these
cells.
The mechanism by which aurothiomalate reduces OB2-1
binding activity is presently unclear. However, studies into
the interactions of other proteins with this drug suggest two
possible mechanisms. As mentioned above, aurothiomalate is
able to interfere with the DNA binding of steroid receptors.
This is achieved by chelating the zinc ion required for the
structural integrity of the receptor zinc finger DNA-binding
domain (Handel et al., 1991). If OB2-1 requires zinc for
optimal binding activity, then chelation may account for the
effect of aurothiomalate. In support of this hypothesis, we
have found that 1,10-orthophenanthroline is also capable of
reducing OB2-4 binding activity (unpublished results). This
assay is often used as a diagnostic test for zinc finger-
containing transcription factors (van Huijsduijnen et al.,
1987), however recent studies on OB2-1 have indicated that it
is not a member of this group of proteins (Bosher et al.,
1995). Aurothiomalate is also known to interact with
cysteine-rich proteins such as metallothionein (Crooke, 1986).
Indeed, Au(I) compounds are transported through cells by a
non-ATP-dependent 'ligand exchange shuttle' mechanism,
whereby Au(I) is passed between different extracellular and
intracellular thiol-containing compounds, in particular the
cysteine amino acids in target proteins. This leads to an
accumulation of Au(I) compounds within the nucleus
(Crooke, 1986). Another colloidal gold compound, auranofin
(l-thio-P-D-glucopyranose 2, 3, 4, 6-tetraaceto-S-triethylphos-
phine gold) inhibits DNA polymerase cEp and herpes simplex
type 1-induced DNA polymerase by this interaction with
important cysteine residues within proteins (Crooke, 1986).
As many transcription factors have been shown to have
important cysteine residues within their DNA-binding
domains (Xanthoudakis et al., 1992), it remains possible that
aurothiomalate interacts with critical cysteine residues in the
OB2-1 DNA-binding domain. The pKa of target cysteine
amino acids may also be important since a second gold
compound, Au(I) N-acetylcysteine, does not alter OB2-1
DNA binding activity (unpublished results). Once we have
cloned OB2-1, we will examine in detail the exact mechanism
of the binding inhibition by aurothiomalate.
At present aurothiomalate and related Au(I) compounds
are principally used clinically in the management of refrac-
tory rheumatoid arthritis (Sadler, 1982; Crooke, 1986).
Although several gold compounds possess some anti-tumour
activity, for example against the B16 melanoma, L1210
leukaemia, M5076 reticulum cell sarcoma, intraperitoneally
implanted P388 leukaemia and the 16/c mammary adenocar-
cinoma (Crooke, 1986; Dhubhgaill and Sadler, 1993), no
gold-based drugs have progressed to routine clinical use as
anti-tumour agents.
Aurothiomalate itself is too non-specific to use as an anti-
tumour agent given its action on steroid receptors (Handel et
al., 1991). We have also found it to be non-specifically toxic
to most mammary-derived cell lines after extended (7 days)
exposure in tissue culture (unpublished observations). Never-
theless, this compound provides a paradigm for a novel
approach to the down-regulation of c-erbB-2 expression in
tumours, and it is possible that related, more specific com-
pounds may be developed as novel transcriptional antagon-
ists to limit tumour growth. One attractive feature of
targeting transcription factors is their dependence on
separate, discrete structural domains for both DNA binding
and transactivation. This 'modular' nature permits the con-
sideration of drugs that act either by abrogating DNA bind-
ing or alternatively by interrupting protein-protein contacts
at the transcription initiation complex. Although empirical
methods have largely been adopted in the development of
drugs that act at a transcriptional level (Peterson and Baich-
wal, 1993), elucidation of the events that underlie drug-
nuclear protein interactions may in future allow the logical
design of transcriptional inhibitors for c-erbB-2 or indeed
other important tumour antigens.
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